Helius Medical Technologies Files 8-K on Shareholder Nominations
Ticker: HSDT · Form: 8-K · Filed: May 31, 2024 · CIK: 1610853
| Field | Detail |
|---|---|
| Company | Helius Medical Technologies, Inc. (HSDT) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-nomination, 8-k
TL;DR
Helius Medical Tech is filing an 8-K about shareholder nominations for the board. Get ready for proxy season.
AI Summary
On May 30, 2024, HELIUS MEDICAL TECHNOLOGIES, INC. filed an 8-K report detailing shareholder nominations for its upcoming annual meeting. The filing indicates that the company is preparing for shareholder engagement regarding board composition and corporate governance.
Why It Matters
This filing signals the company's proactive approach to shareholder engagement and the nomination process for its board of directors, which can impact future strategic decisions.
Risk Assessment
Risk Level: low — The filing is a routine procedural disclosure related to shareholder nominations and does not indicate any immediate financial or operational risks.
Key Players & Entities
- HELIUS MEDICAL TECHNOLOGIES, INC. (company) — Registrant
- May 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 642 Newtown Yardley Road, Suite 100 Newtown, PA 18940 (address) — Principal executive offices
- (215) 944-61 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on shareholder nominations for HELIUS MEDICAL TECHNOLOGIES, INC.'s upcoming annual meeting.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported in this filing is May 30, 2024.
In which state was HELIUS MEDICAL TECHNOLOGIES, INC. incorporated?
HELIUS MEDICAL TECHNOLOGIES, INC. was incorporated in Delaware.
What is the company's principal executive office address?
The company's principal executive office address is 642 Newtown Yardley Road, Suite 100 Newtown, PA 18940.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (215) 944-61.
Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-05-31 16:30:11
Key Financial Figures
- $0.001 — hich registered Class A Common Stock, $0.001 par value HSDT The Nasdaq Stock Mar
Filing Documents
- hsdt-20240530x8k.htm (8-K) — 37KB
- hsdt-20240530x8k001.jpg (GRAPHIC) — 7KB
- 0001558370-24-008834.txt ( ) — 173KB
- hsdt-20240530.xsd (EX-101.SCH) — 3KB
- hsdt-20240530_lab.xml (EX-101.LAB) — 16KB
- hsdt-20240530_pre.xml (EX-101.PRE) — 10KB
- hsdt-20240530x8k_htm.xml (XML) — 5KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. Helius Medical Technologies, Inc. (the "Company") expects to hold its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on Thursday, June 27, 2024 and has fixed the closing of business on May 28, 2024 as the record date for the Annual Meeting. Because the date of the Annual Meeting has been changed by more than 30 days from the anniversary date of the 2023 Annual Meeting of Stockholders, the Company is providing the due date for submission of any qualified stockholder proposal. Pursuant to applicable Securities and Exchange Commission ("SEC") rules and the Company's Second Amended and Restated Bylaws (the "Bylaws"), the deadline for the submission of proposals to be included in the Company's proxy materials and the deadline for the submission of director nominations to be brought before the Annual Meeting by a stockholder is the close of business on June 10, 2024. Written notice for any such proposals, nominations or other business must be received by the Company at its principal executive office (Helius Medical Technologies, Inc., Attention: Secretary, 642 Newtown Yardley Road, Suite 100, Newtown, Pennsylvania 18940) by the applicable deadline and must comply with the procedures and requirements of applicable SEC rules and the Company's Bylaws. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HELIUS MEDICAL TECHNOLOGIES, INC. Dated: May 31, 2024 By: /s/ Jeffrey S. Mathiesen Jeffrey S. Mathiesen Chief Financial Officer, Treasurer and Secretary 3